Health: used to treat menopause, menstrual disorders and endometriosis, lutenyl and luteran would cause a tumor “over-risk”
The tumor would develop from meninges, these membranes that wrap the brain and spinal cord. This sur-risk was observed in women exposed to macroprogestative drugs based on nomestrol (lutenyl and generics) and chlormadinone (luteran and generic) acetate.
Used to treat menopause , menstrual disorders and endometriosis , lutenyl and luteran as well as their generics would cause a “over-risk” of Méningioma, a tumor “ most often benign” , alerts the national drug safety agency on Wednesday, June 17 in a press release.
"Based on an epidemiological study carried out in a very large number of patients by the EPI-Phare scientific interest group and confirming this over-risk, a scientific committee of the ANSM has issued preliminary recommendations for use and surveillance, pending a consultation phase which will be organized in the fall, in particular with health professionals and patients" , can be read in this press release.
Tumors in the menting
The tumor would develop from meninges, these membranes that wrap the brain and spinal cord. This sur-risk was observed in women exposed to macroprogestative drugs based on nomestrol (lutenyl and generics) and chlormadinone (luteran and generic) acetate. In 2019, nearly 400,000 women used these drugs, according to the ANSM.
The epidemiological study, the results of which were presented on June 8, “ highlights a significant increase in the risk with the dose used, the duration of treatment and the age of the patient ". And to explain: “ Women treated more than six months by nomigestrol or chlormadinone acetate are exposed to a risk multiplied respectively by 3.3 and 3.4 compared to the basic risk, then by 12.5 from a cumulative dose corresponding to five years of treatment for nomestrol acetate and by 7 from a cumulative dose corresponding to three and a half years Chlormadinone .
In addition, recalls the national drug safety agency, the risk of meningioma “ leading to intracranial surgery ” increased sharply with age: it is “three times higher for women aged 35 to 44 than for those aged 25 to 34 ”.
MRI recommended in case of symptoms
The ANSM invites health professionals to inform their patients of the risk of meningioma, reassess the relevance of treatment with lutenyl, luteran and generic, taking into account the individual benefit-risk, while limiting the duration of use of these drugs as well as their dosages with effective minimum doses. The agency also recommends brain MRI in the event of symptoms evocative of meningioma.
Patients treated with nomestrol or chlormadinone acetate are invited to consult their doctor. A brain MRI can be offered to them if they are over 35 years old and have been using these drugs for over five years.
"If you have questions, talk about it with your doctor ," said the ANSM in its press release, which adds: " In this context and with regard to the results of the epidemiological study, we invite health professionals and patients to initiate common reflection as to the opportunity to initiate or continue treatment with these drugs."
https://www.francetvinfo.fr/sante/medicament/sante-sanises-pour-traiter-la-menopause-les-roubles-menstruelles-et-lendometriose-le-lutenyl-et -The-Luteran-Procote-Un-sur-Risque-de-Tumor-Benigne_4010919.html? FBCLID = IWAR2QTHAKZQCHG-6K0VBOW9ODX0ADGMTGRZUQJ8K54LGTYX8ARBAIOZPTI
Health: used to treat menopause, menstrual disorders and endometriosis, lutenyl and luteran would cause a tumor “over-risk”
Find the other Amavea articles here
